Heparin dosing in patients undergoing coronary intervention

American Journal of Cardiology

Volumn 82, Issue 8 SUPPL. 1, 1998, Pages 19P-24P

  Popma, Jeffrey J ^a   Prpic, Ross ^b   Lansky, Alexandra J ^b   Piana, Robert ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; THROMBIN INHIBITOR;

ANTICOAGULATION; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; HEART MUSCLE ISCHEMIA; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; MOLECULAR WEIGHT; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTOPENIA;

ANTICOAGULANTS; CORONARY DISEASE; DRUG MONITORING; HEMORRHAGE; HEPARIN; HUMANS; THROMBOCYTOPENIA; WHOLE BLOOD COAGULATION TIME;

EID: 0031728987     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00759-0     Document Type: Article

References (58)

1. Myler RK, Shaw RE, Stertzer SH, Hecht HS, Ryan C, Rosenblum J, Cumberland DC, Murphy MC, Hansell HN, Hidalgo B. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol 1992;19:1641-165.
2. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-96.
3. de Feyter PJ, van den Brand M, Jaarman GJ, van Domburg R, Serruys PW, Suryapranata H, Laarman G. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management and follow-up. Circulation 1991;83:927-936.
4. Detre KM, Holmes DR Jr, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP, Dorros GR, Bentivoglio LG, Kent KM, Myler RK. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-750.
5. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic, and therapeutic profile. J Am Coll Cardiol 1992;19:926-935.
6. Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 1986;6:312-320.
7. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 1987;75:636-642.
8. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719.
9. Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:660-671.
10. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
11. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1570.
12. Grayburn PA, Willard JE, Brickner ME, Eichhorn EJ. In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: evidence for inadequate heparinization. Cathet Cardiovasc Diagn 1991;23:141-143.
13. Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, van Dijk R, van den Bos AA, Umans VAWM, Fox KAA, Close P, Deckers JW, for the HELVETICA Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763.
14. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
15. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IM-PACT-II (Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II). Lancet 1997;349:1422-1428.
16. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435.
17. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
18. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
19. Miller MO. Heparin-induced thrombocytopenia. Cleve Clin J Med 1989;56:483-490.
20. Gupta BK, Savage MP, Brest AN. Acute myocardial infarction during coronary angioplasty associated with heparin-induced thrombocytopenia. Cathet Cardiovasc Diagn 1995;35:42-46.
21. Almeida JI, Coats R, Liem TK, Silver D. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 1998;27:309-316.
22. Solomon HM, Mullins RE, Lyden P, Thompson P, Hudoff S. The diagnostic accuracy of bedside and laboratory coagulation: procedures used to monitor the anticoagulation status of patients treated with heparin. Am J Clin Pathol 1998;109:371-378.
23. Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992;26:260-263.
24. Nath FC, Muller DW, Rosenschein U, Ellis SG, Topol EJ. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Can J Cardiol 1993;9:797-801.
25. Pitney MR, Kelly SA, Allan RM, Giles RW, McCredie M, Walsh WF. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty. Cathet Cardiovasc Diagn 1996;37:145-150.
26. Bowers J, Ferguson JJ III. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol 1994;17:357-361.
27. Ferguson JJ. All ACTs are not created equal. (Editorial.) Texas Heart Inst J 1992;19:1-3.
28. Hillegass WB, Brott BC, Haura EB, Harrington RA, Phillips HR, Stack RS, Califf RM. Patient-specific heparin dosing during angioplasty. (Abstr.). J Am Coll Cardiol 1995;25(suppl):391A.
29. Brack MJ, More RS, Hubner PJ, Gershlick AH. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times. Blood Coagul Fibrinolysis 1993;4:183-186.
30. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin. A word of caution when both are used concomitantly. Arch Intern Med 1987;147:857-860.
31. Miller RD. Heparin resistance prior to cardiopulmonary bypass. Anesthesiology 1986;64:504-507.
32. Marmur JD, Sharma SK, Kantrowitz NE, Gupta V, Cocko T, Duwwi S, Ambrose JA. Angiographically complex lesions are associated wtih increased levels of thrombin generation and activity following PTCA. (Abstr.) J Am Coll Cardiol 1995;25(suppl):155A.
33. Verheugt FWA, Liem A, Zijlstra F, Marsh RC, Veen G, Bronzwaer JGF. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. J Am Coll Cardiol 1998;31:289-293.
34. Liem AL, Zijlstra F, Hoorntje JCA, Suryapranata H, de Boer MJ, Verheugt FWA. Randomized trial of high dose bolus heparin before primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) Study, (Abstr.) Circulation 1998;98(suppl).
35. Laskey MAL, Deutsch E, Hirshfeld JW Jr, Kussmaul WG, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990;65:179-182.
36. Laskey MAL, Deutsch E, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol 1990;65:1425-1429.
37. Kolansky DM, Shapiro TA, Laskey WK. Prolonged heparin therapy for occlusive intracoronary thrombus. Cathet Cardiovascular Diagn 1993;30:150-152.
38. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
39. The PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. N Engl J Med 1998;339:436-443.
40. Bull BS, Korman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-684.
41. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-240.
42. Frierson JH, Dimas AP, Simpfendorfer CC, Pearce G, Miller M, Franco I. Is aggressive heparinization necessary for elective PTCA? Cathet Cardiovasc Diagn 1993;28:279-282.
43. Aguirre FV, Ferguson JJ, Blankenship JC, Pieper KS, Taylor M, Harrington RA, Rund M, Caracciolo EA, Donohue TJ, Califf RM, Lincoff AM, Tcheng JE, Topol EJ, for the IMPACT-II Investigators. Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: results from the IMPACT-II Trial. (Abstr.) J Am Coll Cardiol 1996;23(suppl):83A.
44. Hillegass WB, Brott BC, Narins CR, Haura EB, Phillips HR, Stack RS, Califf RM. Predictors of blood loss and bleeding complications after angioplasty. (Abstr.) J Am Coll Cardiol 1994;23(suppl):69A.
45. Popma JJ, Satler LF, Pichard AD, Kent KM, Campbell A, Chuang YC, Clark C, Merritt AJ, Bucher TA, Leon MB. Vascular complications after balloon and new device angioplasty. Circulation 1993;88:1569-1578.
46. Koch KT, Piek JJ, de Winter RJ, David GK, Mulder K, Tijssen JG, Lie KI. Safety of low dose heparin in elective coronary angioplasty. Heart 1997;77:517-522.
47. Pesola GR, Pesola DA. Heparin dosing for percutaneous coronary angioplasty: use of body surface area to improve initial activated clotting time values. Clin Cardiol 1997;20:1006-1009.
48. Boccara A, Benamer H, Juliard JM, Aubry P, Goy P, Himbert D, Karrilon GJ, Steg PG. A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J 1997;18:631-635.
49. Friedman HZ, Cragg DR, Glazier SM, Gangadharan V, Marsalese DL, Schreiber TL, O'Neill WW. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994;24:1214-1219.
50. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-782.
51. Rabah M, Mason D, Muller DWM, Hundley R, Kugelmass AD, Weiner B, Cannon L, O'Neill WW, Safian RD. Heparin after Percutaneous Intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary interventions. J Am Coll Cardiol 1998; (In press).
52. Fail PS, Maniet AR, Banka VS. Subcutaneous heparin in postangioplasty management: comparative trial with intravenous heparin. Am Heart J 1993;126:1059-1067.
53. Chow WH, Fan K, Chow TC. Use of low molecular weight heparin in postangioplasty management. Int J Cardiol 1997;58:83-85.
54. Zidar JP. Rationale for low-molecular weight heparin in coronary stenting. Am Heart J 1997;134:S81-S87.
55. Sutton JM, Anderson K, for the EPIC Study Group. Body weight and heparin dosing influence bleeding complications with c7E3 antiplatelet antibody. (Abstr.) Circulation 1993;88(suppl I):I-209.
56. Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Am J Cardiol 1997;79:286-291.
57. Sundlof DW, Reprkpattanapitat P, Wongpraparut N, Kotler MN, Jacobs LE, Yazdanfar S. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring angioplasty. (Abstr.) J Am Coll Cardiol 1998;31(suppl A):238A.
58. Cohen M, Bigonzi F, Le louer V, Gosset F, Fromell GJ, Goodman S. One year follow-up of the ESSENCE Trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction). (Abstr.) J Am Coll Cardiol 1998;31(suppl A):79A.